Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
114 hedge funds and large institutions have $718M invested in Sio Gene Therapies Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 48 increasing their positions, 20 reducing their positions, and 29 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 20
3% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 29
1% more funds holding
Funds holding: 113 → 114 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
47% less call options, than puts
Call options by funds: $40.5M | Put options by funds: $75.9M
72% less capital invested
Capital invested by funds: $2.52B → $718M (-$1.8B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
+$41.6M |
| 2 |
SCM
Sio Capital Management
New York
|
+$23.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$20.8M |
| 4 |
IPLA
Ice Pond Lane Advisers
New York
|
+$20.3M |
| 5 |
DM
Deerfield Management
New York
|
+$17.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$84.5M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$80.1M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$47.9M |
| 4 |
D.E. Shaw & Co
New York
|
-$34M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$23.2M |
SIOX Hedge Fund Activity: Q3 2017 in Review
114 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q3 2017, worth a combined $718M — down 72% from $2.52B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SIOX positions and 29 closed out — a net gain of 1 holder — while 48 added to existing stakes and 20 trimmed.
The largest buyer was PointState Capital, adding an estimated $41.6M. The largest seller was Fidelity Investments, cutting an estimated $84.5M.
- 114 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q3 2017, up from 113 in Q2 2017.
- Funds reported $718M of Sio Gene Therapies Inc. Common Stock stock for Q3 2017, down 72% quarter-over-quarter.
- 30 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q3 2017 and 29 closed out, a net change of +1 holder.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q3 2017 was PointState Capital, an estimated $41.6M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q3 2017 was Fidelity Investments, an estimated $84.5M sold.
Based on aggregated 13F filings for Q3 2017.